EMA committee backs extending AstraZeneca's H5N1 pandemic nasal flu vaccine to adults
- On 15 October 2026 the EMA's human medicines committee adopted a positive opinion extending the indication of AstraZeneca's H5N1 pandemic vaccine.
- The change removes the upper age limit; the H5N1 vaccine had covered children and adolescents from 12 months to under 18 years.
- The AstraZeneca H5N1 vaccine is a live attenuated nasal spray used only after an official pandemic declaration.
- No phase 3 efficacy trial has tested the H5N1 vaccine itself; the assessment relied on immune-response studies and related vaccines.
The European Medicines Agency's human medicines committee (CHMP) adopted a positive opinion on 15 October 2026 recommending an extension of indication for AstraZeneca's H5N1 pandemic influenza vaccine. The change removes the restriction to children and adolescents aged 12 months to under 18 years, so adults would also be covered.
What the vaccine is
It is a nasal spray containing a live attenuated A/Vietnam/1203/2004 (H5N1) strain, built on the same components as the seasonal nasal flu vaccine. It has had conditional EU authorisation since 2016 and is used only after an official pandemic declaration, when the H5N1 strain would be replaced with the circulating pandemic strain. It is given as one spray in each nostril, with a second dose at least 4 weeks later.
Also read: EMA committee recommends Nyxoid naloxone nasal spray for opioid overdose without a prescription
The evidence
No phase 3 efficacy trial has tested the vaccine itself, because a new pandemic vaccine cannot be tested before a pandemic. The assessment relied on three studies in 107 adults plus large paediatric studies of related seasonal and pandemic live attenuated vaccines. The most common side effects are decreased appetite, headache, runny or blocked nose and malaise.
Next step
The opinion goes to the European Commission for a decision, and the vaccine remains under additional monitoring.
Sources: European Medicines Agency (EMA), Contagion Live
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What did the EMA recommend for AstraZeneca's H5N1 vaccine?
On 15 October 2026 the CHMP recommended removing the upper age limit from AstraZeneca's H5N1 pandemic vaccine, so it would cover adults as well as children from 12 months.
How is AstraZeneca's H5N1 pandemic vaccine given?
AstraZeneca's H5N1 vaccine is a nasal spray: 0.1 mL in each nostril, with a second dose at least 4 weeks later.
Is the H5N1 pandemic vaccine being used now?
No. AstraZeneca's H5N1 pandemic vaccine is used only after an official influenza pandemic declaration and in line with official recommendations.
Was the H5N1 nasal vaccine tested in a large efficacy trial?
No phase 3 efficacy trial has tested the H5N1 nasal vaccine itself; its assessment used immune-response studies in 107 adults and paediatric studies of related vaccines.
What are the common side effects of the H5N1 nasal vaccine?
The most common side effects of the H5N1 nasal vaccine are decreased appetite, headache, runny or blocked nose and malaise.



